As mentioned above, B cells can enhance the evolution of NASH to fibrosis [58], and anti-BAFF treatment can attenuate NAFLD but not attenuate hepatic fibrosis as measured by collagen deposition, the hepatic expression of collagen-1a, α-smooth muscle actin, and mononuclear cell infiltration in a mouse model [61]. The gene discussed is TNFSF13B; the disease is metabolic dysfunction-associated steatohepatitis.